MARKET
IPO

AEON

AEON BIOPHARMA INC
AEON
NASDAQ
Upcoming IPOs
Expected Listing Date: - -
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-10.69~-9.36
122.27~139.74
-4.52~-3.96
307.95M~351.94M
Biotechnology & Medical Research
2021-09-17
Public Filing
View Prospectus
Pending
Offering
Price Range: 14.00~16.00
Shares to be Issued: 5000.00K
Pending
Offering End Date
Offering Price: Pending
Post IPO Outstanding: 22.00M
Listed
BRIEF-AEON Biopharma Files To Withdraw IPO Plans
reuters.com · 12/29/2021 21:27
UPDATE 1-GIC-backed clinical trial firm WCG withdraws U.S. IPO plans
reuters.com · 10/13/2021 16:28
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets amid the broader market strength.
Benzinga · 10/10/2021 15:59
7 Things to Know About the Upcoming $330 Million AEON Biopharma (AEON) IPO
Street Insider · 10/05/2021 06:19
No Data
Learn about the latest financial forecast of AEON. Analyze the recent business situations of AEON BIOPHARMA INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.97%
Pharmaceuticals & Medical Research
+1.48%
Key Executives
President/Chief Executive Officer
Marc Forth
Chief Financial Officer/Primary Contact
Chris Carr
Vice President - Operations
Del Stagg
Executive Officer
Chad Oh
No Data
No Data
About AEON
AEON Biopharma, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions. The biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a molecular weight of 900 kDa. Its initial development programs for ABP-450 are focused on migraine, cervical dystonia and gastroparesis. Migraine is a neurological condition characterized by recurrent episodes of headaches. The Company is developing ABP-450 for the preventative treatment of migraine, which is inclusive of both chronic migraine and episodic migraine. Cervical dystonia is a neurological condition characterized by involuntary muscle contractions of the neck which may present as spasms, contractions or abnormal posture. Gastroparesis is a gastrointestinal disorder characterized by the slowing or stoppage of movement of food and liquid from the stomach to the small intestine.

Webull offers kinds of AEON BIOPHARMA INC stock information, including NASDAQ:AEON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AEON stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AEON stock methods without spending real money on the virtual paper trading platform.